Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
Study Results
Related Studies
Nesiritide in Transplant-Eligible Management of Congestive Heart Failure-TMAC
This study has been terminated.
( DSMC acknowledged no safety concerns with the trial, recommending that the trial be terminated due to slow enrollment. )
Study NCT00338455 Information provided by Scios, Inc.
First Received: June 16, 2006 Last Updated: September 28, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Congestive Heart Failure
Cardiac Transplantation
Renal Failure
Renal Insufficiency
Additional conditions recognized in this trial
Heart Failure
Kidney Failure
More general conditions related to this trial
Cardiovascular Diseases
Heart Diseases
Kidney Diseases
Urologic Diseases
Additional drug interventions recognized in this trial
Dobutamine
Milrinone
Natriuretic Peptide, Brain
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Agonists
Adrenergic beta-Agonists
Autonomic Agents
Cardiotonic Agents
Cardiovascular Agents
Enzyme Inhibitors
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Phosphodiesterase Inhibitors
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Protective Agents
Sympathomimetics
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
Scios, Inc.
Back to top of Main Content